Title: Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral Therapy
Authors: Deebii, N*, Orluwene, CG, Korubo, K. I, and Njoku, B
DOI: http://dx.doi.org/10.18535/jmscr/v3i10.20
Abstract
The present study examines the effects of antiretroviral therapy (ART) on two basic immuno-haematological parameters over time. We performed a retrospective study of HIV-infected treatment-naïve patients starting a first line ART between June 2014 and January 2015, and followed-up for 12 weeks. On the whole, 254HIV-infected treatment naive patients were enrolled: 100 patients on tenoforvir (TDF) based regimen was compared with 102 and 52 non-TDF based regimen and treatment-naïve patients respectively. Samples were collected at three different points (at baseline, 4 weeks and 12 weeks).CD4 and haemoglobin (Hb) were found to be significantly higher (p=0.001) in the TDF group as compared to non-TDF groups after 12 weeks of follow-up, although there was no significant difference between the Non-TDF group and ART-naive group at 4 and 12 weeks in both parameters. These results demonstrate that the initiation of a TDF based-regimen is followed by an increase in lymphocyte proliferation and lymphocyte-mediated cytotoxicity compared to other non-TDF based-regimen group. However we suggest that TDF should be part of an antiretroviral regimen in immunosuppressed patients at risk of anaemia.
Keywords: HIV, Tenoforvir (TDF), CD4 and immunosuppressed
References
1. MellorsJW, Munoz A, Giorgi JV.Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12); 946-954.
2. Egger M, May T, Chene G. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360(9327):119-129.
3. Martin J, Volberding P. (2010). HIV and premature aging: a field still in its infancy. Annals of Internal Medicine; 153: 477-9.
4. World Health Organization. World Health Report on HIV/AIDS 2004, 2004.
5. Mavigner M, Delobel P, Cazabat M, Dubois M. HIV-1 Residual Viremia Correlates with persistent T-cell activation in poor immunological responders to combination Antiretroviral therapy. PLos ONE2009: 4(10). e7658.doi:10.1371/journal.pone.0007658
6. Kaufmann GR, Perrin L, Pantaleo G. CD4 T lymphocyte recovery in individuals with advance HIV-1 infection receiving potent ART for 4 years: the swiss HIV cohort study. Arch intern. Med. 2003;163 (18)2187-2195.
7. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19(6):593-601.
8. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ: Impact of viral hepatitis co- infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18(8):1169-1177.
9. Akinola NO, Olasode O, Adediran IA, Onayemi O, Mu- rainah A, Irinoye O, et al. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substi- tute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis 2004; 39(4): 579-81.
10. Spacek LA, Griswold M, Quinn TC, Moore RD. Total lym- phocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in re- source-limited settings. AIDS 2003; 17(9): 1311-7.
11. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource- limited settings. AIDS 2003; 17(4): 541-5.
12. Barrios A, Garcia-Benayas T, Gozalez-Lahoz J, Soriano V. Teno- fovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18: 960-3.
13. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5: 563-73.
14. Rodriguez-Novoa S, Labarga P, D’Avolio A, Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064- 6